IPROOV/EUROSTAR
6.12.2021 08:02:11 CET | Business Wire | Press release
iProov , the world leader in biometric face authentication technology, and Eurostar , the high-speed passenger rail service linking the UK with mainland Europe, have announced that their trial of a contactless fast-track service, SmartCheck, is now live.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211205005029/en/
SmartCheck enables passengers to complete secure ticket verification and UK exit check on their mobile devices prior to travel. As part of the trial, Business Premier and Carte Blanche ticket holders will be able to scan their identity documentation using their iPhones before arriving at the station, completing a brief biometric face scan to verify that they are the genuine holder of the identity document. The biometric face verification, which uses iProov’s Genuine Presence Assurance technology, is then linked to their e-ticket, with confirmation sent to the passenger.
On arrival at St Pancras International station, passengers proceed through a dedicated SmartCheck lane. A brief face scan at the ticket gate verifies that the customer has completed the ticket check, with no sharing of paper or electronic tickets needed. A second face scan at the UK Exit Check allows Eurostar to verify that the passenger has completed their passport information, again replacing the need for travelers to hand over documentation.
SmartCheck aims to revolutionize the travel experience by making it completely effortless for the passenger, while maximizing privacy and increasing reassurance through improved security. The aim is to eliminate queues and expedite the boarding process to further improve customer satisfaction, especially for frequent travelers.
The concept is being brought to train travel as part of the First of a Kind 2020 competition run by Innovate UK, funded by the Department for Transport (DfT). The initiative supports research, development and innovation in the UK rail industry. At this time, the trial involves a limited number of invited passengers and is focused on the check-in and exit control processes operated by Eurostar at St Pancras Station and not the UK or Schengen Entry controls.
“This secure, convenient and privacy-protecting technology will make life easier and safer for travelers around the world,” said Andrew Bud, Founder and CEO, iProov. “The days of rooting around in your bag for your passport or hoping that your phone battery doesn’t run out before you show your e-ticket at the gate are over. It’s effortless and convenient while also delivering the reassurance and security that travelers expect.”
“We are committed to working closely with governments to introduce new tools and technology that streamline the check in and border process,” said Gareth Williams, Strategy Director and Company Secretary, Eurostar. “Face biometric technology, which we start trialling today, is a fast and contactless solution which will enable secure passenger checks to take place more efficiently and provide a seamless start to the Eurostar customer journey.”
“Our investment into the First of a Kind competition, supporting ingenious inventions on our rail network, is driving real-world innovations as we build the railway of tomorrow,” said Grant Shapps, Transport Secretary. “The brand new contactless travel technology from iProov and Eurostar is a window into the future of border control, of smoother, more seamless and convenient journeys.”
iProov’s Genuine Presence Assurance technology enables organizations to securely verify the identity of consenting online individuals in a way that is completely effortless for the user. A brief, multi-dimensional biometric face scan combines light, time and space to verify that a remote user is the right person, a real person, and that they are authenticating in real time. This highly secure process, supported by iProov’s active threat management system, protects against spoof attacks and can be used on any smartphone, tablet or computer with a user-facing camera.
The trial was developed in close partnership with Eurostar and WorldReach Software, now part of global identity and data security company, Entrust . All personal data is processed in compliance with GDPR law, with full passenger consent. It is not shared with any party outside the trial and is deleted within six hours of the user travelling.
iProov technology is in use throughout the world, with customers including the US Department of Homeland Security, the UK Home Office, the NHS, the Australian Taxation Office, the Singapore Government and many banks and enterprises.
About iProov
Launched in 2013, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter .
About Eurostar
For more information, please contact press.office@eurostar.com
Eurostar is the high-speed passenger service linking London St. Pancras International with city centre stations in mainland Europe, via the Channel Tunnel. Eurostar was established in 1994 as a partnership between three railway companies: SNCF, SNCB and LCR (London and Continental Railways). On 1 September 2010, Eurostar became a single, unified corporate entity owned by three shareholders: SNCF, SNCB and LCR. LCR’s holding was transferred to the Treasury in 2014 and sold by the UK government to a consortium comprising Caisse de Depot et Placement du Quebec (CDPQ) and Hermes Infrastructure in May 2015.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211205005029/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
